Chad Bates, MD
Family Medicine · Kingsport, TNNPI 1003926353
Payments from drug & device makers
Across 150 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- AbbVie$406
- Novartis$244
- GSK$174
- Astellas Pharma US Inc$158
- AstraZeneca$127
- plus $747 from 20 others
What the payments were for
- Speaking & faculty fees$452%
- Food & beverage$2,25898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $447 |
| AbbVie | 36 | $406 |
| Novartis | 14 | $244 |
| GSK | 11 | $174 |
| Astellas Pharma US Inc | 8 | $158 |
| AstraZeneca | 8 | $127 |
| Pfizer | 5 | $102 |
| Dexcom, Inc. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Merck | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Bayer | 3 | $49 |
| Amarin Pharma, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Amgen(2 entities) | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
How this compares
$2,304 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $160,322 |
| JardianceEmpagliflozin | 88 | $108,276 |
| OzempicSemaglutide | 82 | $106,637 |
| XareltoRivaroxaban | 126 | $97,600 |
| MounjaroTirzepatide | 60 | $60,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $38,081 |
| TrulicityDulaglutide | 20 | $34,817 |
| JanuviaSitagliptin Phosphate | 33 | $27,492 |
| Spiriva RespimatTiotropium Bromide | 14 | $16,790 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,877 |
| Spiriva HandihalerTiotropium Bromide | 13 | $14,222 |
| FarxigaDapagliflozin Propanediol | 12 | $14,034 |
| Rosuvastatin Calcium | 870 | $13,796 |
| Atorvastatin Calcium | 807 | $13,288 |
| Losartan Potassium | 749 | $9,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $160,322171 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $32 | $125,066102 claims |
| Novo NordiskOzempic | $447 | $106,63782 claims |
| Johnson & JohnsonXarelto | $15 | $97,600126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $35 | $95,57580 claims |
| GSKTrelegy Ellipta | $174 | $38,08139 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $127 | $27,53838 claims |
| MerckJanuvia | $60 | $27,49233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Kingsport
- Emily HubbsKingsport$2.8M
- Curtis JantziKingsport$1.3M
- Warren JonesKingsport$27K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.